Effective therapy with the neuroleptic thioridazine as an adjunct to second line of defence drugs, and the potential that thioridazine offers for new patents that cover a variety of ''New Uses''

Leonard Amara, Miguel Viveiros, J. Molnár, Jette E. Kristiansen

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

New and active infections of tuberculosis continue to increase globally. Although antibiotic susceptible infections can be readily cured with isoniazide and rifampicin, infections resistant to these two antibiotics, named Multi- Drug Resistant TB (MDR TB), are problematic for therapy, extol high costs in terms of human suffering and finances, and when these MDR infections progress to Extensive Drug Resistant TB (XDR TB) status, they are not only difficult to treat, they produce high levels of mortality regardless of therapeutic modality employed. The neuroleptic thioridazine (TZ) has been shown to have wide spectrum in vitro and ex vivo activities against antibiotic susceptible, MDR and XDR strains, and has been successfully used for curing mice of active tuberculosis produced by antibiotic susceptible and MDR strains, and has cured 10 out of 12 XDR TB patients when used in combination with three antibiotics to which the XDR TB patients were non-responsive. Mycobacterium tuberculosis TZ has been recommended for "Compassionate Therapy" of MDR/XDR TB infections whose prognoses are significantly serious and anticipated to result in mortality. This review of TZ activity and its potential to cure MDR/XDR TB supports the contention that this neuroleptic offers patenting opportunities for "New Use". The motivation for patents therefore is expected to rapidly bring TZ to the forefront for therapy of MDR/XDR TB and therefore, the striving for new patents is expected to contribute to the prevention of new infections of antibiotic resistant tuberculosis.

Original languageEnglish
Pages (from-to)84-87
Number of pages4
JournalRecent Patents on Anti-Infective Drug Discovery
Volume6
Issue number2
DOIs
Publication statusPublished - 2011

Fingerprint

Extensively Drug-Resistant Tuberculosis
Thioridazine
Patents
Antipsychotic Agents
Anti-Bacterial Agents
Infection
Pharmaceutical Preparations
Tuberculosis
Therapeutics
Mortality
Rifampin
Psychological Stress
Mycobacterium tuberculosis
Motivation
Costs and Cost Analysis

Keywords

  • Cure
  • Ex vivo activities
  • Extensive drug resistance (XDR TB)
  • In vitro activities
  • In vivo activities
  • Multidrug resistance (MDR TB)
  • Patent as "new use"
  • Thioridazine

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Drug Discovery

Cite this

@article{a363f69b3083489e81e80eaf44462cab,
title = "Effective therapy with the neuroleptic thioridazine as an adjunct to second line of defence drugs, and the potential that thioridazine offers for new patents that cover a variety of ''New Uses''",
abstract = "New and active infections of tuberculosis continue to increase globally. Although antibiotic susceptible infections can be readily cured with isoniazide and rifampicin, infections resistant to these two antibiotics, named Multi- Drug Resistant TB (MDR TB), are problematic for therapy, extol high costs in terms of human suffering and finances, and when these MDR infections progress to Extensive Drug Resistant TB (XDR TB) status, they are not only difficult to treat, they produce high levels of mortality regardless of therapeutic modality employed. The neuroleptic thioridazine (TZ) has been shown to have wide spectrum in vitro and ex vivo activities against antibiotic susceptible, MDR and XDR strains, and has been successfully used for curing mice of active tuberculosis produced by antibiotic susceptible and MDR strains, and has cured 10 out of 12 XDR TB patients when used in combination with three antibiotics to which the XDR TB patients were non-responsive. Mycobacterium tuberculosis TZ has been recommended for {"}Compassionate Therapy{"} of MDR/XDR TB infections whose prognoses are significantly serious and anticipated to result in mortality. This review of TZ activity and its potential to cure MDR/XDR TB supports the contention that this neuroleptic offers patenting opportunities for {"}New Use{"}. The motivation for patents therefore is expected to rapidly bring TZ to the forefront for therapy of MDR/XDR TB and therefore, the striving for new patents is expected to contribute to the prevention of new infections of antibiotic resistant tuberculosis.",
keywords = "Cure, Ex vivo activities, Extensive drug resistance (XDR TB), In vitro activities, In vivo activities, Multidrug resistance (MDR TB), Patent as {"}new use{"}, Thioridazine",
author = "Leonard Amara and Miguel Viveiros and J. Moln{\'a}r and Kristiansen, {Jette E.}",
year = "2011",
doi = "10.2174/157489111796064542",
language = "English",
volume = "6",
pages = "84--87",
journal = "Recent Patents on Anti-Infective Drug Discovery",
issn = "1574-891X",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Effective therapy with the neuroleptic thioridazine as an adjunct to second line of defence drugs, and the potential that thioridazine offers for new patents that cover a variety of ''New Uses''

AU - Amara, Leonard

AU - Viveiros, Miguel

AU - Molnár, J.

AU - Kristiansen, Jette E.

PY - 2011

Y1 - 2011

N2 - New and active infections of tuberculosis continue to increase globally. Although antibiotic susceptible infections can be readily cured with isoniazide and rifampicin, infections resistant to these two antibiotics, named Multi- Drug Resistant TB (MDR TB), are problematic for therapy, extol high costs in terms of human suffering and finances, and when these MDR infections progress to Extensive Drug Resistant TB (XDR TB) status, they are not only difficult to treat, they produce high levels of mortality regardless of therapeutic modality employed. The neuroleptic thioridazine (TZ) has been shown to have wide spectrum in vitro and ex vivo activities against antibiotic susceptible, MDR and XDR strains, and has been successfully used for curing mice of active tuberculosis produced by antibiotic susceptible and MDR strains, and has cured 10 out of 12 XDR TB patients when used in combination with three antibiotics to which the XDR TB patients were non-responsive. Mycobacterium tuberculosis TZ has been recommended for "Compassionate Therapy" of MDR/XDR TB infections whose prognoses are significantly serious and anticipated to result in mortality. This review of TZ activity and its potential to cure MDR/XDR TB supports the contention that this neuroleptic offers patenting opportunities for "New Use". The motivation for patents therefore is expected to rapidly bring TZ to the forefront for therapy of MDR/XDR TB and therefore, the striving for new patents is expected to contribute to the prevention of new infections of antibiotic resistant tuberculosis.

AB - New and active infections of tuberculosis continue to increase globally. Although antibiotic susceptible infections can be readily cured with isoniazide and rifampicin, infections resistant to these two antibiotics, named Multi- Drug Resistant TB (MDR TB), are problematic for therapy, extol high costs in terms of human suffering and finances, and when these MDR infections progress to Extensive Drug Resistant TB (XDR TB) status, they are not only difficult to treat, they produce high levels of mortality regardless of therapeutic modality employed. The neuroleptic thioridazine (TZ) has been shown to have wide spectrum in vitro and ex vivo activities against antibiotic susceptible, MDR and XDR strains, and has been successfully used for curing mice of active tuberculosis produced by antibiotic susceptible and MDR strains, and has cured 10 out of 12 XDR TB patients when used in combination with three antibiotics to which the XDR TB patients were non-responsive. Mycobacterium tuberculosis TZ has been recommended for "Compassionate Therapy" of MDR/XDR TB infections whose prognoses are significantly serious and anticipated to result in mortality. This review of TZ activity and its potential to cure MDR/XDR TB supports the contention that this neuroleptic offers patenting opportunities for "New Use". The motivation for patents therefore is expected to rapidly bring TZ to the forefront for therapy of MDR/XDR TB and therefore, the striving for new patents is expected to contribute to the prevention of new infections of antibiotic resistant tuberculosis.

KW - Cure

KW - Ex vivo activities

KW - Extensive drug resistance (XDR TB)

KW - In vitro activities

KW - In vivo activities

KW - Multidrug resistance (MDR TB)

KW - Patent as "new use"

KW - Thioridazine

UR - http://www.scopus.com/inward/record.url?scp=79959996814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959996814&partnerID=8YFLogxK

U2 - 10.2174/157489111796064542

DO - 10.2174/157489111796064542

M3 - Article

C2 - 21548876

AN - SCOPUS:79959996814

VL - 6

SP - 84

EP - 87

JO - Recent Patents on Anti-Infective Drug Discovery

JF - Recent Patents on Anti-Infective Drug Discovery

SN - 1574-891X

IS - 2

ER -